For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A222001

Trial Overview

Official Title

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy

Study Purpose

To test whether a low or high dose of oxybutynin can reduce hot flashes. 

Diagnosis

Hormone therapy treatments for your prostate cancer can cause side effects such as hot flashes.

Eligibility

Prostate Cancer

Men receiving androgen deprivation therapy (hormone therapy)

Intervention

Group 1: Patients will take oxybutynin 2.5 ml two times a day for up to six weeks.

Group 2: Patients will take placebo 2.5 ml two times a day for up to six weeks.

Group 3: Patients will take oxybutynin 5.0 ml two times a day for up to six weeks.

Group 4: Patients will take placebo 5.0 ml two times a day for up to six weeks.

Patients will also complete questionnaires before you start study treatment, daily during treatment, and at the end of treatment.

For more information, visit Clinicaltrials.gov

Key Participation Requirements
Gender
Male
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
A222001